Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COnCERTO trial of neoadjuvant chemotherapy versus upfront surgery in obstructive colon cancer after diverting stoma
2024-516456-17-00Phase 3Authorised
- Sponsor
- Rouen University Hospital
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, levoleucovorin and capecitabine in colon adenocarcinoma (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Success of a full curative therapeutic strategy. Planned start Sep 2024; status: authorised.
02
Drugs
oxaliplatinfluorouracillevoleucovorincapecitabine
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on 2024-516456-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516456-17-00.